pdufa.bio

Casgevy (exagamglogene autotemcel)

Page updated ·next FDA decision on the calendar ·Data as of Nov 12, 2026 2:24 AM ET

The FDA approved Casgevy (exagamglogene autotemcel) on Jul 1, 2026. 2 FDA decisions on record below. Every date links its source.

CRSP catalyst hub · VRTX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Jul 1, 2026 ✓ ApprovedCRSPFDA decision · Jul 1, 2026 ✓ ApprovedVRTX

Questions

When is Casgevy (exagamglogene autotemcel)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for Casgevy (exagamglogene autotemcel); 2 FDA decisions are on record below.

What happened at Casgevy (exagamglogene autotemcel)'s most recent FDA decision?

On Jul 1, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has Casgevy (exagamglogene autotemcel) been approved by the FDA?

Yes. The FDA approved an application for Casgevy (exagamglogene autotemcel) on Jul 1, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.